Navigation Links
Royalty Pharma Announces Offer May Lapse (Be Withdrawn)
Date:6/13/2013

HARE REPURCHASE PROGRAM. 

  • While the deadline for holders of Elan American Depository Receipts held in street name to vote electronically through BroadRidge has passed, such holders may nevertheless vote or change their vote by asking their custodian, BroadRidge or proxy voting agent (ISS or Glass Lewis) to do so manually until 3 p.m. EDT today, Thursday, June 13.  Shareholders needing assistance in voting are urged to contact MacKenzie Partners, Royalty Pharma's proxy solicitor, at +1 212 929 5500.
  • Holders of Elan Ordinary Shares have until 10:00 a.m. Irish time on Saturday, June 15 to vote their proxies through Computershare (Ireland).

Royalty Pharma notes that Elan only publicly announced that it had received "unsolicited enquiries" three days ago, more than three months after Royalty Pharma's proposal first became public and only after it appeared to be gaining investor support.

There can be no assurance that Elan will conduct a sale process, that any sale process that is conducted will be conducted fairly, or that any proposal to acquire Elan will be presented to Elan Shareholders.

Even if Elan does conduct a sales process, given that Royalty Pharma's offer of $13.00 plus an up to $2.50 CVR has been deemed "grossly inadequate" by Elan, there can be no assurance that Elan will not conclude that all other offers they receive are "grossly inadequate".

IT IS EASY FOR ELAN TO RUN A SALE PROCESS THAT PRODUCES NO RESULT BECAUSE ELAN DEEMS ALL OFFERS INADEQUATE OR CONCLUDES THAT ANOTHER STRATEGIC ALTERNATIVE PRODUCES MORE VALUE.

THERE IS NO UNCERTAINTY REGARDING ROYALTY PHARMA'S CURRENT OFFER:  $13 IN CASH PER SHARE PLUS AN UP TO $2.50 CVR.  THERE IS SUBSTANTIAL UNCERTAINTY REGARDING ANY ALTERNATIVE PATH ELAN MAY PRESENT.

VOTE "AGAINST" ALL FOUR RESOLUTIONS OF THE ELAN EGM

Capitalized terms used bu
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. PDL BioPharma Provides Second Quarter 2013 Royalty Revenue Guidance of $143 Million
2. Royalty Pharma Files Judicial Review Proceedings
3. Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan
4. Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit
5. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
6. Royalty Pharma Acceptances Announcement
7. Royalty Pharma Responds To Elans Tysabri Valuation
8. Royalty Pharma Response To Elans "Categorical View On Value"
9. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
10. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
11. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014  LABSCO, the leading specialty sales ... to hospitals, physician office laboratories and alternate ... agreement with Sysmex America.  This agreement is ... the Sysmex XS-1000 i ™, Sysmex pocH-100 ... Automated Hematology Analyzers. The agreement ...
(Date:9/18/2014)... 2014  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... ended June 30, 2014. Quarter Ended ... June 30, 2014 increased $492,000, or 18%, to $3.2 ... June 30, 2013, due primarily to an increase of ... the Company,s largest customer, partially offset by an aggregate ...
(Date:9/18/2014)... --  MacPractice,s MacPractice MD MU version 5.0 has ... designates that the software is capable of supporting eligible ... Meaningful Use measures required to qualify for funding under ... MU version 5.0 was certified on June 6, 2014 ... National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant in ...
Breaking Medicine Technology:LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... , , ... Incorporated, (IDEV) an emerging leader in the development and marketing ... patient was enrolled in the Company,s FDA-approved multi-center clinical trial ... for the treatment of biliary and peripheral artery disease (PAD) ...
... RYE, N.Y., Aug. 24 Curemark Founder and CEO Dr. ... International Epigenomics, Sequencing 2009 Conference at Harvard Medical School on ... to address this cutting-edge conclave is particularly significant, since epigenetics ... occur without a change in the DNA sequence. Presenters at ...
Cached Medicine Technology:IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent 2Curemark CEO Presents at Epigenomics Conference 2
(Date:9/18/2014)... true: exercise is good for you. But new research ... have an added benefit for cancer patients undergoing chemotherapy. ... melanoma, found that combining exercise with chemotherapy shrunk tumors ... associate professor in the School of Nursing and director ... was the senior author on the study, which appears ...
(Date:9/18/2014)... The American College of Chest Physicians (CHEST) together ... at the annual congress of CTS that CHEST ... Clinicians specializing in pulmonary, critical care, and sleep ... participate in the event, slated for spring 2016. ... rich educational experiences including hands-on simulation training, keynote ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 ... the Neighborhood Mission (Misión Barrio Adentro), which ... the healthcare system (see Section 6.1.3.). In ... in an Autonomous Service of Pharmaceutical Elaborations ... plant, which provides medicines at a cheaper ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading ... and co-founder John Cassimatis was named as one ... 2014, recognizing the region’s top healthcare and life ... of the year. , The Innovation Awards celebrate ... continue to shape the medical industry in Greater ...
(Date:9/18/2014)... Salt Lake City, UT (PRWEB) September 18, 2014 ... across North America will be recognizing their shared fundraising ... on Thursday, Sept. 25. , The first-ever Dance ... of more than $20 million projected to be raised ... at their community’s CMN Hospital. Donations generated through Dance ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2
... services company standardizes on AVG Network Edition , ... ... Pyramid Healthcare, founded in 1999, provides behavioral healthcare services for ... and behavioral problems. The company has 23 locations across Pennsylvania, ...
... (CTI) (Nasdaq and MTA: CTIC) announced today that they ... with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) ... the initial $7.5 million payment in connection with the ... up to an additional $15 million in product sales ...
... Immucor, Inc.,(Nasdaq: BLUD ), a global leader ... reported financial results,for the fiscal second quarter ended November 30, ... -- Revenue for the fiscal second quarter ... the same period last year. , ...
... of America,Inc. announced the formation of ROSA of ... ROSA of South Alabama is a joint ... P.C., Monroeville Radiation -,Oncology, P.C., and South Alabama ... of America, Inc. ROSA of South,Alabama will ...
... The following is a statement by Lois Aronstein, ... State address put forth recommendations on a number of ... financial security of New Yorkers of all ages.AARP commends ... Plus Program to 200 percent of the federal poverty ...
... also bolsters tie between vitamin D and the brain ... have identified nine genes that might make people more ... confirmed earlier reports that a variation in the vitamin ... risk for Alzheimer,s. Low levels of vitamin D ...
Cached Medicine News:Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 2Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 3Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 4Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 3Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 4Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 2Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 3Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 4Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 5Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 6Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 7Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 8Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 9Health News:Ambulatory Services of America, Inc. Announces Joint Venture with Gulf Coast Cancer Centers 2Health News:9 Genes Are Linked to Alzheimer's 2
... Ad-Techs Foramen Ovale Electrodes provide you ... These electrodes offer the same proven design ... that they are placed using an introducing ... a smaller electrode body diameter, 3 to ...
... The Small Joint Ball Electrode ... in small joint applications. With its ... tip, controlled capsuloligamentous or tendinous tissue ... When used in conjunction with the ...
... is designed to replace the carpal scaphoid bone. ... pole which fits under a shelf formed in ... suture hole on the proximal hole for suture ... the early postoperative period until a firm capsuloligamentous ...
... two-piece Titanium (Ti-6Al-4V) screw offered in two ... of lengths. The two pieces are loaded ... A single instrument set contains all items ... Standard and Mini Kompressor Compression Screws. , ...
Medicine Products: